Exciting results. Well done EBR and holders. On the webinar John said "The trial crushed the endpoints"
Binary de-risk out of the way! Now for the formalities with FDA and commercialisation. First peer review publication out soon.
This will be a quick process with the Breakthrough designation and EBR get to go to front of line. John said not need for lengthy emails and delayed responses because breakthrough designations allows for informal phone discussions for advice etc.
M & A could come at anytime. Well done holders.
Wise passes both primary endpoints, page-6
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EBR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.025(2.39%) |
Mkt cap ! $329.6M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.04 | $120.6K | 113.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 170 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 2700 | 1 |
View Market Depth
| Last trade - 15.46pm 09/08/2024 (20 minute delay) ? |
| EBR (ASX) Chart |